

الرقم ١٢٤٨ / م. ١ / ٥ / ٦

التاريخ : 20 / 11 / 2017م

للسيد

\* بورصة عمان \*

\* السهم \*

المحترمين

السادة / هيئة الأوراق المالية

الموضوع : البيانات المالية الربع سنوية


تحية طيبة وبعد

إشارة الى كتابكم رقم 17/02704/1/12 بتاريخ 2017/11/16 والوارد لنا يوم الأحد الموافق 2017/11/19م والمتضمن عدم تزويدكم بالبيانات المالية باللغة الانجليزية للربع الثالث لعام 2017م ، يرجى التكرم بالعلم أن سبب التأخير يعود لسفر الشخص المفوض بالتوقيع عن شركة التدقيق الخارجي ( شركة سمان وشركاه ) خارج البلاد علماً أنه تم تزويدكم بالبيانات المالية باللغة العربية للربع الثالث بتاريخ 2017/10/29م .

كما نؤكد لكم التزامنا التام بالمستقبل بقرار مجلس مفوضي الهيئة رقم ( 2017/19 ) .

وتفضلوا بقبول فائق الاحترام والتقدير ،،،

مدير عام الشركة  
احمد الأحمد



نسخة :-

- بورصة عمان
- قسم شؤون المساهمين
- الصادر العام

AL BILAD FOR MEDICAL SERVICES COMPANY  
(PUBLIC SHAREHOLDING COMPANY)  
AMMAN - JORDAN

INTERIM CONDENSED CONSOLIDATED FINANCIAL  
STATEMENTS "UNAUDITED"  
TOGETHER WITH REVIEW REPORT  
FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2017

AL BILAD FOR MEDICAL SERVICES COMPANY  
(PUBLIC SHAREHOLDING COMPANY)  
AMMAN - JORDAN

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)  
TOGETHER WITH REVIEW REPORT  
FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2017

---

| <u>Contents</u>   | <u>Page</u> |
|---|-------------|
| Review report   | -           |
| Interim condensed consolidated statement of financial position                            | 1           |
| Interim condensed consolidated statement of profit or loss and other comprehensive income | 2           |
| Interim condensed consolidated statement of changes in equity                             | 3           |
| Interim condensed consolidated statement of cash flows                                    | 4           |
| Notes forming part of the interim condensed consolidated financial statements             | 5-9         |

## Review Report

To the shareholders of  
**Al Bilad For Medical Services Company**  
(Public Shareholding Company)  
Amman - Jordan

### Introduction

We have reviewed the interim condensed consolidated statement of financial position of **Al Bilad For Medical Services Company (Public Shareholding Company)** as at 30 September 2017 and the interim condensed consolidated statements of profit or loss and other comprehensive income, changes in equity and cash flows for the nine months then ended, and a summary of significant accounting policies and other explanatory information. Management is responsible for the preparation and fair presentation of these interim condensed consolidated financial statements in accordance with IAS 34 "Interim Financial Reporting". Our responsibility is to express a conclusion on these interim condensed consolidated financial statements based on our review.

### Scope of review

We conducted our review in accordance with International Standard on Review Engagements (2410) "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.


### Emphasis of matter

We would like to draw attention to note number (5) which discloses the impairment of Libyan debts provision and our conclusion has not been adjusted in respect of this matter.

### Conclusion

Based on our review, nothing has come to our attention that causes us believe that the interim condensed consolidated financial statements do not present fairly from all material respects the interim condensed financial position for **Al Bilad For Medical Services Company (Public Shareholding Company)** as at 30 September 2017 and its interim condensed consolidated financial performance and its interim condensed consolidated cash flows for the nine months then ended, in accordance with IAS 34 "Interim Financial Reporting".

**Samman & Co**

  
**Rami Samman**  
License (594)



**19 October 2017**  
**Amman - Jordan**

Al Bilad For Medical Services Company  
(Public Shareholding Company)  
Amman - Jordan

Interim condensed consolidated statement of financial position  
As at 30 September 2017

|  | Note | 30 September<br>2017<br>JD<br>(Unaudited) | 31 December<br>2016<br>JD<br>(Audited) |
|--|------|---|--|
| <b><u>Assets</u></b>   |      |   |  |
| <b>Non current assets</b>  |      |   |  |
| Property and equipment   | (4)  | 17,450,585                                | 16,937,921                             |
| Investment property  |      | 2,888,288                                 | 2,888,288                              |
| Investments in associate company   |      | 2,008,069                                 | 2,139,357                              |
| Investments in financial assets at fair value through other comprehensive income                                     |      | 243,706                                   | 243,706                                |
| Intangible assets  |      | 80,710                                    | 66,978                                 |
|  |      | <u>22,671,358</u>                         | <u>22,276,250</u>                      |
| <b>Current assets</b>  |      |   |  |
| Medicines and medical Supplies   |      | 966,297                                   | 1,228,992                              |
| Trade and other receivables  | (5)  | 17,891,703                                | 17,097,824                             |
| Cash and cash equivalents  |      | 3,398,234                                 | 4,667,350                              |
|  |      | <u>22,256,234</u>                         | <u>22,994,166</u>                      |
| <b>Total Assets</b>  |      | <u><b>44,927,592</b></u>                  | <u><b>45,270,416</b></u>               |
| <b><u>Equity and Liabilities</u></b>   |      |   |  |
| <b><u>Equity</u></b>   |      |   |  |
| Authorized capital   | (6)  | 30,000,000                                | 30,000,000                             |
| Paid up capital  |      | 30,000,000                                | 30,000,000                             |
| Statutory reserve  |      | 2,234,037                                 | 2,234,037                              |
| Accumulated change in fair value of investments in financial assets at fair value through other comprehensive income |      | (406,085)                                 | (257,186)                              |
| Retained earning   |      | 2,747,706                                 | 2,639,367                              |
| <b>Total Equity</b>  |      | <u><b>34,575,658</b></u>                  | <u><b>34,616,218</b></u>               |
| <b><u>Liabilities</u></b>  |      |   |  |
| <b>Non current liabilities</b>   |      |   |  |
| Loans and bank facilities  |      | 111,150                                   | 289,933                                |
| <b>Current liabilities</b>   |      |   |  |
| Trade and other payables   | (7)  | 7,366,185                                 | 8,521,680                              |
| Loans and bank facilities  |      | 2,857,128                                 | 1,461,275                              |
| Income tax provision   | (8)  | 17,471                                    | 381,310                                |
|  |      | <u>10,240,784</u>                         | <u>10,364,265</u>                      |
| <b>Total liabilities</b>   |      | <u><b>10,351,934</b></u>                  | <u><b>10,654,198</b></u>               |
| <b>Total equity and liabilities</b>  |      | <u><b>44,927,592</b></u>                  | <u><b>45,270,416</b></u>               |

The Interim condensed consolidated financial statements on pages [1] to [9] were approved and authorized for issue by the Board of Directors on 19 October 2017 and were signed by:

General Manager

Chairman

Al Bilad For Medical Services Company  
(Public Shareholding Company)  
Amman - Jordan

Interim condensed consolidated statement of profit or loss and other comprehensive  
income (Unaudited)  
for the nine months ended 30 September 2017

|  | Note | For the three months ended 30 |             | For the nine months ended 30 |             |
|--|------|-------------------------------|-------------|------------------------------|-------------|
|  |      | September                     |             | September                    |             |
|  |      | 2017                          | 2016        | 2017                         | 2016        |
|  |      | JD                            | JD          | JD                           | JD          |
| Revenue  |      | 2,854,674                     | 4,664,340   | 8,751,504                    | 13,377,490  |
| Cost of revenue  |      | (1,846,437)                   | (2,483,720) | (5,670,940)                  | (7,520,290) |
| Gross profit   |      | 1,008,237                     | 2,180,620   | 3,080,564                    | 5,857,200   |
| Other revenue  |      | 261,313                       | 153,315     | 566,760                      | 450,132     |
| Administrative expenses  |      | (1,205,655)                   | (1,715,311) | (3,412,415)                  | (6,939,732) |
| Operating profit (loss)  |      | 63,895                        | 618,624     | 234,909                      | (632,400)   |
| Share of profits of equity accounted associate   |      | 4,343                         | 6,276       | 17,601                       | 16,105      |
| Financing costs  |      | (39,889)                      | (33,911)    | (121,198)                    | (107,835)   |
| Profit (loss) for the year before tax  |      | 28,349                        | 590,989     | 131,312                      | (724,130)   |
| Income tax   | (8)  | (12,192)                      | (191,087)   | (22,973)                     | (459,459)   |
| Profit (loss) for the year   |      | 16,157                        | 399,902     | 108,339                      | (1,183,589) |
| Other comprehensive income   |      |                               |             |                              |             |
| Change in fair value of investments in<br>financial assets at fair value through other<br>comprehensive income |      | (71,273)                      | (19,547)    | (148,899)                    | (46,896)    |
| Total comprehensive income   |      | (55,116)                      | 380,355     | (40,560)                     | (1,230,485) |
| Profit (Loss) Per Share - Piaster/ share   |      |                               |             | 0.004                        | (0.039)     |

Al Bilad For Medical Services Company  
(Public Shareholding Company)  
Amman - Jordan

Interim condensed consolidated statement of changes in equity (Unaudited)  
for the nine months ended 30 September 2017

|                          | Paid up capital   | Statutory reserve | Accumulated change in<br>fair value of investments<br>in financial assets at<br>fair value through other<br>comprehensive income | Retained earnings | Total             |
|--------------------------|-------------------|-------------------|--|-------------------|-------------------|
|                          | JD                | JD                | JD   | JD                | JD                |
| <u>30 September 2017</u> |                   |                   |  |                   |                   |
| 1 January 2017           | 30,000,000        | 2,234,037         | (257,186)  | 2,639,367         | 34,616,218        |
| Loss for the period      | -                 | -                 | (148,899)  | 108,339           | (40,560)          |
| <u>30 September 2017</u> | <u>30,000,000</u> | <u>2,234,037</u>  | <u>(406,085)</u>   | <u>2,747,706</u>  | <u>34,575,658</u> |
| <u>30 September 2016</u> |                   |                   |  |                   |                   |
| 1 January 2016           | 22,000,000        | 2,234,037         | (294,771)  | 5,160,904         | 29,100,170        |
| Capital increase         | 8,000,000         | -                 | -  | -                 | 8,000,000         |
| Dividend                 | -                 | -                 | -  | (1,100,000)       | (1,100,000)       |
| Loss for the period      | -                 | -                 | (46,896)   | (1,183,589)       | (1,230,485)       |
| <u>30 September 2016</u> | <u>30,000,000</u> | <u>2,234,037</u>  | <u>(341,667)</u>   | <u>2,877,315</u>  | <u>34,769,685</u> |

Al Bilad For Medical Services Company  
(Public Shareholding Company)  
Amman - Jordan

Interim condensed consolidated statement of cash flows (Unaudited)  
for the nine months ended 30 September 2017

|  | Note | 2017<br>JD              | 2016<br>JD              |
|--|------|-------------------------|-------------------------|
| <b><u>Operating activities</u></b>                                     |      |                         |                         |
| Profit (loss) for the year before tax                                  |      | 131,312                 | (724,130)               |
| <i>Adjustments for:</i>  |      |                         |                         |
| Depreciation and amortization  | (4)  | 1,074,261               | 1,336,209               |
| Impairment of receivables  |      | (4,452)                 | 3,140,661               |
| Share of profits of equity accounted associate                         |      | (17,601)                | (16,105)                |
| Financing costs  |      | 121,198                 | 107,835                 |
|  |      | <u>1,304,718</u>        | <u>3,844,470</u>        |
| Medicines and medical Supplies   |      | 262,694                 | (117,308)               |
| Trade and other receivables  | (5)  | (789,431)               | (942,143)               |
| Trade and other payables   | (7)  | (1,155,496)             | (779,384)               |
| Net cash flow (used in) generated from operating activities before tax |      | (377,515)               | 2,005,635               |
| Paid income tax  |      | (386,814)               | (1,291,023)             |
| Net cash flow (used in) generated from operating activities            |      | <u>(764,329)</u>        | <u>714,612</u>          |
| <b><u>Investing activities</u></b>                                     |      |                         |                         |
| Purchase of property and equipment                                     |      | (320,085)               | (619,928)               |
| Purchase of intangible assets  |      | (29,932)                | (32,810)                |
| Projects under construction  |      | (1,250,640)             | (650,759)               |
| Net cash flow used in investing activities                             |      | <u>(1,600,657)</u>      | <u>(1,303,497)</u>      |
| <b><u>Financing activities</u></b>                                     |      |                         |                         |
| Loans and bank facilities  |      | 1,217,068               | (2,227,643)             |
| Paid financing costs   |      | (121,198)               | (107,835)               |
| Capital increase   | (6)  | -                       | 8,000,000               |
| Dividends  | (6)  | -                       | (1,100,000)             |
| Net cash flows generated from financing activities                     |      | <u>1,095,870</u>        | <u>4,564,522</u>        |
| Net (Decrease) Increase in cash and cash equivalents                   |      | (1,269,116)             | 3,975,637               |
| Cash and cash equivalents - beginning of the year                      |      | 4,667,350               | 757,311                 |
| Cash and cash equivalent - end of the year                             |      | <u><u>3,398,234</u></u> | <u><u>4,732,948</u></u> |



Al Bilad For Medical Services Company  
(Public Shareholding Company)  
Amman - Jordan

Notes forming part of the Interim condensed consolidated financial statements  
For the nine months ended 30 September 2017

---

**1) General**

Al Bilad For Medical Services Company was established on 26 November 1996 as a public shareholding company in the Register of Public Shareholding Companies under No. 323.

The main objective of the company is to establish a general hospital to provide health, preventive, diagnostic and therapeutic services.

The company's main address is: Amman - Arjan.

The following are the names of the board members:

| <u>Name</u>  | <u>Position</u> |
|--|-----------------|
| HE Sheikh Fahad bin Mohammed bin Saleh Al-Athel  | Chairman        |
| HE Dr. Nayef Hayel Falih Al Fayez  | Deputy Chairman |
| Arab General Medical Services Company Ltd. represented by<br>Turki Bin Fahad Mohammed Al Athel | Board Member    |
| Mohammed Tayseer Morshed Al Haj Hassan Abu Rajab   | Board Member    |
| Khaled Ahmed Refaat  | Board Member    |
| Zuhair Kamal Khamis Jaber  | Board Member    |
| Hashem Odeh Al Fadhel Al Fadhel  | Board Member    |
| Mustafa Ahmed Abdulhafeez Salhab   | Board Member    |
| Saleh Hassan Saleh Abu Rumah   | Board Member    |

The interim condensed consolidated financial statements of the Group include the financial statements of the Parent Company (Al Bilad For Medical Services Company), its subsidiary and associate companies, the following is information about the subsidiary:

| <u>Company</u>                                       | <u>Country of<br/>incorporation</u> | <u>Activity</u>                                    | <u>Percentage of<br/>ownership%</u> |
|--|-------------------------------------|--|-------------------------------------|
| Al Bilad Al Khadra Real Estate<br>Investment Company | Jordan                              | Possession of land to implement<br>company's goals | 100                                 |

Notes forming part of the Interim condensed consolidated financial statements (continued)  
For the nine months ended 30 September 2017

---

**2) Summary of significant accounting policies**

**Basis of preparation**

The interim condensed consolidated financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting and in accordance with local standard. They do not include all disclosures that would otherwise be required in a complete set of financial statements and should be read in conjunction with the 2016 annual report.

The preparation of interim condensed consolidated financial statements in compliance with IAS 34 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the company's accounting policies.

The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those used in the preparation of the financial statements for the year ended 31 December 2016. Except for new standards, interpretations and amendments that are effective for the first time for periods beginning on or after 1 January 2017 that will be adopted in the annual financial statements for 2017.

None of the new standards, interpretations and amendments have any material impact on the interim condensed consolidated financial statements.

**Basis of consolidation**

When the Company has control over the investee, it is considered a subsidiary. Control is achieved when all three elements are available: the power in the investee company, the right to variable returns, and the ability to use power to influence the amount of variable returns. The control shall be re-evaluated if any facts or indications of a possible change in any of the above-mentioned elements have occurred.

The consolidated financial statements include the results of the Company and the subsidiary as if they form together a single entity and therefore the transactions and balances between the two companies are fully eliminated.

The consolidated financial statements include the results of the business combination using the acquisition method whereby the assets and liabilities of the subsidiary are recognized at fair value at the date of acquisition and their operating results are taken to the statement of profit or loss and other comprehensive income from the date of acquisition, and its recognitions stops in case of losing control.

**3) Use of estimates and judgments**

There have been no material revisions to the nature and amount of changes in estimates and Judgments used in the annual consolidated financial statements 2016.

**4) Property and equipment**

The additions of property and equipment during the nine months ended 30 September 2017 amounted to JD 1,570,725 (31 December 2016: JD 1,878,993).

The depreciation expense of property and equipment for the nine months ended 30 June 2017 amounted to JD 1,058,061 (30 September 2016: JD 1,277,079).

Notes forming part of the Interim condensed consolidated financial statements (continued)  
For the nine months ended 30 September 2017

5) Trade and other receivables

|   | 30 September<br>2017<br>JD<br>(Unaudited) | 31 December<br>2016<br>JD<br>(Audited) |
|---|---|--|
| Trade receivables   | 23,790,748                                | 23,087,479                             |
| Checks under collection   | 83,414                                    | 36,579                                 |
| Provision for impairment of trade receivables   | (7,124,017)                               | (7,128,468)                            |
| Net trade receivables   | 16,750,145                                | 15,995,590                             |
| Due from related parties  | 1,487                                     | 7,729                                  |
| Accrued revenue   | 502,919                                   | 486,704                                |
| Employees receivables   | 68,400                                    | 45,455                                 |
| Insurances  | 263,345                                   | 263,345                                |
| <br>Total financial assets classified as loans and account<br>receivable other than cash and cash equivalents | <br>17,586,296                            | <br>16,798,823                         |
| <br>Advance payments to contractors   | <br>14,224                                | <br>109,746                            |
| Prepaid expenses  | 126,044                                   | 92,065                                 |
| Other   | 165,139                                   | 97,190                                 |
|   | <u>17,891,703</u>                         | <u>17,097,824</u>                      |

In respect of the receivables incurred by the Libyan Country, the management has not deducted a provision for it as of the date of the interim financial statements. The management will reassess the possibility of collecting these receivables by the end of the fiscal year ended 31 December 2017 based on the meeting held on 23 March 2017 between the Private Hospitals Association and the Libyan Embassy, and related correspondence on 25 September 2017 between each of private hospital Association and Libyan Government.

6) Equity

Capital

The authorized capital is (30) million JD divided into (30) million shares where the value is 1JD per share.

The subscribed capital was increased to JD (30) million instead of JD (22) million through the private placement directed to the shareholders of the group under the Extraordinary General Assembly held on 23 November 2015, the number of shares covered during the subscription period was (8) million shares where the value is 1JD per share.

Notes forming part of the Interim condensed consolidated financial statements (continued)  
For the nine months ended 30 September 2017

**Statutory reserves**

The accumulated amounts in this reserve represents 10% of annual profits before tax and fees and it's not distributable to the shareholders. The group may stop deducting statutory reserves when it reaches 25% of the capital.

However, the group may with the approval of the General Assembly, continue to deduct this annual ratio until this reserve equals the capital of the group in full.

**Accumulated change in fair value of investments in financial assets at fair value through other comprehensive income**

Represents the profits or losses arising from the valuation of financial assets classified as investments in financial assets at fair value through other comprehensive income.

**Retained earnings**

This item contains only profit, loss and dividends.

In accordance with the Board of Directors' meeting held on 21 April 2016, the implementation of the 19th Ordinary General Assembly Decision was approved, that included the distribution of a cash dividend to shareholders by (5%) of the subscribed capital.

**7) Trade and other payables**

|   | 30 September<br>2017 | 31 December<br>2016 |
|---|----------------------|---------------------|
|   | JD                   | JD                  |
|   | (Unaudited)          | (Audited)           |
| Trade payable   | 2,999,331            | 3,358,075           |
| Accrued expenses  | 2,092,696            | 2,153,455           |
| Deferred cheques  | 1,554,839            | 2,392,186           |
| <b>Total financial liabilities other than loans and bank facilities</b> | <b>6,646,866</b>     | <b>7,903,716</b>    |
| Income tax deposits   | 86,979               | 89,981              |
| Social security deposits  | 64,490               | 66,492              |
| Unearned revenue  | 54,372               | -                   |
| Patients deposits   | 50,851               | 61,661              |
| Other   | 462,627              | 399,830             |
|   | <b>7,366,185</b>     | <b>8,521,680</b>    |

Notes forming part of the Interim condensed consolidated financial statements (continued)  
For the nine months ended 30 September 2017

---

8) Income tax provision

The Company has calculated an income tax of JD 22,973 representing 20% of net profit for the nine months ended 30 September 2017, compared to 459,459 JD for the nine months ended 30 September 2016 after deducting the trade receivables and the Share of profits of equity accounted associates. This percentage represents the tax rate expected to be applied by the end of the year.

9) Contingent liabilities

**Lawsuits**

According to correspondence with the group's lawyers, the management has not been able to identify potential financial obligations related to the filed lawsuits, since these lawsuits are at the stage of the exchange of regulations and the outcome of these lawsuits cannot be predicted.

**Bank guarantees**

At the consolidated statement of financial position date, the Group had contingent liabilities against bank guarantees amounted to JD 80,770.

**Letters of credit**

At the consolidated statement of financial position date, the Group had contingent liabilities against letters of credits amounted to JD 221,533.